These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 16574455)

  • 41. Interaction between lopinavir/ritonavir and warfarin.
    Hughes CA; Freitas A; Miedzinski LJ
    CMAJ; 2007 Aug; 177(4):357-9. PubMed ID: 17698824
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Top stories of 2004. Back to the future: lopinavir/ritonavir as "monotherapy".
    Sax PE
    AIDS Clin Care; 2005 Jan; 17(1):4. PubMed ID: 15717366
    [No Abstract]   [Full Text] [Related]  

  • 43. Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and two nucleosides for maintenance therapy of HIV.
    Pulido F; Arribas JR; Delgado R; Cabrero E; González-García J; Pérez-Elias MJ; Arranz A; Portilla J; Pasquau J; Iribarren JA; Rubio R; Norton M;
    AIDS; 2008 Jan; 22(2):F1-9. PubMed ID: 18097218
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Safety and efficacy of a double-boosted protease inhibitor combination, saquinavir and lopinavir/ritonavir, in pretreated children at 96 weeks.
    Bunupuradah T; van der Lugt J; Kosalaraksa P; Engchanil C; Boonrak P; Puthanakit T; Mengthaisong T; Mahanontharit A; Lumbiganon P; Tompkins E; Burger D; Ruxrungtham K; Ananworanich J;
    Antivir Ther; 2009; 14(2):241-8. PubMed ID: 19430099
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Anti-HIV agents. Once-daily lopinavir/ritonavir (Kaletra).
    TreatmentUpdate; 2004 Mar; 16(2):3-4. PubMed ID: 17219667
    [No Abstract]   [Full Text] [Related]  

  • 46. Acquired macroglossia due to lopinavir/ritonavir treatment.
    Vritsali E; Kolokotronis A; Valagouti D; Miteloudis G; Zaraboukas T; Kioses V; Antoniades D
    J Oral Pathol Med; 2005 Jan; 34(1):56-8. PubMed ID: 15610408
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Alopecia induced by lopinavir plus ritonavir therapy in an HIV patient.
    Chrysos G; Mikros S; Kokkoris S; Pastelli A; Kontochristopoulos G
    J Drugs Dermatol; 2007 Jul; 6(7):742-3. PubMed ID: 17763601
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effect of lopinavir/ritonavir monotherapy on quality of life and self-reported symptoms among antiretroviral-naive patients: results of the MONARK trial.
    Spire B; Marcellin F; Cohen-Codar I; Flandre P; Boue F; Dellamonica P; Raffi F; Norton M; Van Philippe N; Delfraissy JF
    Antivir Ther; 2008; 13(4):591-9. PubMed ID: 18672538
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Kaletra OK'd by FDA.
    James JS
    Posit Living; 2000 Nov; 9(9):8, 13. PubMed ID: 12154764
    [No Abstract]   [Full Text] [Related]  

  • 50. Small dense LDL and atherogenic lipid profile in HIV-positive adults: influence of lopinavir/ritonavir-containing regimen.
    Badiou S; De Boever CM; Dupuy AM; Baillat V; Cristol JP; Reynes J
    AIDS; 2003 Mar; 17(5):772-4. PubMed ID: 12646808
    [No Abstract]   [Full Text] [Related]  

  • 51. Efficacy of lopinavir-ritonavir reduced dose in HIV-infected patients.
    Lattuada E; Lanzafame M; Vento S
    AIDS Patient Care STDS; 2011 Aug; 25(8):455-6. PubMed ID: 21718150
    [No Abstract]   [Full Text] [Related]  

  • 52. High incidence of adverse events in healthy volunteers receiving rifampicin and adjusted doses of lopinavir/ritonavir tablets.
    Nijland HM; L'homme RF; Rongen GA; van Uden P; van Crevel R; Boeree MJ; Aarnoutse RE; Koopmans PP; Burger DM
    AIDS; 2008 May; 22(8):931-5. PubMed ID: 18453852
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [An option even for patients with multiple pretreatment].
    MMW Fortschr Med; 2001 Apr; 143 Suppl 1():97. PubMed ID: 11373796
    [No Abstract]   [Full Text] [Related]  

  • 54. Anti-HIV agents. Using only lopinavir/ritonavir (Kaletra).
    TreatmentUpdate; 2008 Jan; 20(1):1-2. PubMed ID: 18320690
    [No Abstract]   [Full Text] [Related]  

  • 55. Hair loss induced by lopinavir-ritonavir.
    Borrás-Blasco J; Belda A; Rosique-Robles D; Casterá E; Abad J; Amorós-Quiles I
    Pharmacotherapy; 2007 Aug; 27(8):1215-8. PubMed ID: 17655521
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Efficacy and tolerability of a fosamprenavir-ritonavir-based versus a lopinavir-ritonavir-based antiretroviral treatment in 82 therapy-naïve patients with HIV-1 infection.
    Calza L; Manfredi R; Pocaterra D; Chiodo F
    Int J STD AIDS; 2008 Aug; 19(8):541-4. PubMed ID: 18663041
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Justified hope after 4 years. Initial therapy still without resistance].
    MMW Fortschr Med; 2003 Apr; 145 Spec No 1():48-9. PubMed ID: 15011588
    [No Abstract]   [Full Text] [Related]  

  • 58. Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP ANRS 127 study.
    Landman R; Capitant C; Descamps D; Chazallon C; Peytavin G; Katlama C; Pialoux G; Bentata M; Brun-Vézinet F; Aboulker JP; Yéni P;
    J Antimicrob Chemother; 2009 Jul; 64(1):118-25. PubMed ID: 19420019
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pharmacokinetics of a once-daily regimen of lopinavir/ritonavir in HIV-1-infected children.
    van der Lee M; Verweel G; de Groot R; Burger D
    Antivir Ther; 2006; 11(4):439-45. PubMed ID: 16856617
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Lack of evidence for an effect of lopinavir/ritonavir on tenofovir renal clearance.
    Ray AS; Wright MR; Rhodes GR
    Clin Pharmacol Ther; 2008 Dec; 84(6):660; author reply 661. PubMed ID: 18615003
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.